These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17942464)

  • 1. Predicting event times in clinical trials when randomization is masked and blocked.
    Donovan JM; Elliott MR; Heitjan DF
    Clin Trials; 2007; 4(5):481-90. PubMed ID: 17942464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting event times in clinical trials when treatment arm is masked.
    Donovan JM; Elliott MR; Heitjan DF
    J Biopharm Stat; 2006 May; 16(3):343-56. PubMed ID: 16724489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting analysis times in randomized clinical trials.
    Bagiella E; Heitjan DF
    Stat Med; 2001 Jul; 20(14):2055-63. PubMed ID: 11439420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting analysis time in event-driven clinical trials with event-reporting lag.
    Wang J; Ke C; Jiang Q; Zhang C; Snapinn S
    Stat Med; 2012 Apr; 31(9):801-11. PubMed ID: 22344853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous Bayesian adaptive randomization based on event times with covariates.
    Cheung YK; Inoue LY; Wathen JK; Thall PF
    Stat Med; 2006 Jan; 25(1):55-70. PubMed ID: 16025549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weibull prediction of event times in clinical trials.
    Ying GS; Heitjan DF
    Pharm Stat; 2008; 7(2):107-20. PubMed ID: 17377932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of event times in the REMATCH Trial.
    Ying GS; Heitjan DF
    Clin Trials; 2013 Apr; 10(2):197-206. PubMed ID: 23321264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials.
    Wijeysundera DN; Austin PC; Hux JE; Beattie WS; Laupacis A
    J Clin Epidemiol; 2009 Jan; 62(1):13-21.e5. PubMed ID: 18947971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Joint monitoring and prediction of accrual and event times in clinical trials.
    Zhang X; Long Q
    Biom J; 2012 Nov; 54(6):735-49. PubMed ID: 22907686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sample size determination for constrained longitudinal data analysis.
    Lu K; Mehrotra DV; Liu G
    Stat Med; 2009 Feb; 28(4):679-99. PubMed ID: 19051207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptive randomization for multiarm comparative clinical trials based on joint efficacy/toxicity outcomes.
    Ji Y; Bekele BN
    Biometrics; 2009 Sep; 65(3):876-84. PubMed ID: 19173694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
    Schmidli H; Bretz F; Racine-Poon A
    Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the estimation of change from baseline in a continuous outcome measure in the clinical trial setting.
    Mayer-Hamblett N; Kronmal RA
    Contemp Clin Trials; 2005 Feb; 26(1):2-16. PubMed ID: 15837448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporating intermediate binary responses into interim analyses of clinical trials: a comparison of four methods.
    Whitehead A; Sooriyarachchi MR; Whitehead J; Bolland K
    Stat Med; 2008 May; 27(10):1646-66. PubMed ID: 17886243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sample sizes for clinical trials with time-to-event endpoints and competing risks.
    Schulgen G; Olschewski M; Krane V; Wanner C; Ruf G; Schumacher M
    Contemp Clin Trials; 2005 Jun; 26(3):386-96. PubMed ID: 15911472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imputation of a true endpoint from a surrogate: application to a cluster randomized controlled trial with partial information on the true endpoint.
    Nixon RM; Duffy SW; Fender GR
    BMC Med Res Methodol; 2003 Sep; 3():17. PubMed ID: 14507420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal sample size determinations from an industry perspective based on the expected value of information.
    Willan AR
    Clin Trials; 2008; 5(6):587-94. PubMed ID: 19029207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian clinical trials.
    Berry DA
    Nat Rev Drug Discov; 2006 Jan; 5(1):27-36. PubMed ID: 16485344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Data mining and statistically guided clinical review of adverse event data in clinical trials.
    Southworth H; O'Connell M
    J Biopharm Stat; 2009 Sep; 19(5):803-17. PubMed ID: 20183445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.